Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 Sep 1;5(9):e2229442.
doi: 10.1001/jamanetworkopen.2022.29442.

Consensus-Based Recommendations on Priority Activities to Address Acute Kidney Injury in Children: A Modified Delphi Consensus Statement

Affiliations
Observational Study

Consensus-Based Recommendations on Priority Activities to Address Acute Kidney Injury in Children: A Modified Delphi Consensus Statement

Stuart L Goldstein et al. JAMA Netw Open. .

Abstract

Importance: Increasing evidence indicates that acute kidney injury (AKI) occurs frequently in children and young adults and is associated with poor short-term and long-term outcomes. Guidance is required to focus efforts related to expansion of pediatric AKI knowledge.

Objective: To develop expert-driven pediatric specific recommendations on needed AKI research, education, practice, and advocacy.

Evidence review: At the 26th Acute Disease Quality Initiative meeting conducted in November 2021 by 47 multiprofessional international experts in general pediatrics, nephrology, and critical care, the panel focused on 6 areas: (1) epidemiology; (2) diagnostics; (3) fluid overload; (4) kidney support therapies; (5) biology, pharmacology, and nutrition; and (6) education and advocacy. An objective scientific review and distillation of literature through September 2021 was performed of (1) epidemiology, (2) risk assessment and diagnosis, (3) fluid assessment, (4) kidney support and extracorporeal therapies, (5) pathobiology, nutrition, and pharmacology, and (6) education and advocacy. Using an established modified Delphi process based on existing data, workgroups derived consensus statements with recommendations.

Findings: The meeting developed 12 consensus statements and 29 research recommendations. Principal suggestions were to address gaps of knowledge by including data from varying socioeconomic groups, broadening definition of AKI phenotypes, adjudicating fluid balance by disease severity, integrating biopathology of child growth and development, and partnering with families and communities in AKI advocacy.

Conclusions and relevance: Existing evidence across observational study supports further efforts to increase knowledge related to AKI in childhood. Significant gaps of knowledge may be addressed by focused efforts.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Goldstein reported receiving personal fees from BioPorto Diagnostics, grant support and personal fees from Medtronic Inc, NuWellis Inc, Leadiant, personal fees from MediBeacon Inc, stock options and personal fees from Baxter Healthcare, grant support and personal fees from SeaStar Medical, and grants from ExThera Medical outside the submitted work. Dr Akcan-Arikan reported receiving financial support for research from Bioporto research funds paid to her institution outside the submitted work. Dr Askenazi reported receiving personal fees from Baxter, Nuwellis, Medtronic, Seastar, and Bioporto, and financial support for research from Zorro-Flow outside the submitted work; in addition, Dr Askenazi reported having a patent for Zorro-Flow, an external urine collection device pending, and a patent for continuous renal replacement therapy (CRRT) advancements pending. Dr Bagshaw reported receiving personal fees from Baxter and BioPorto during the conduct of the study. Dr Barreto reported receiving financial support for research from FAST Biomedical Consultant and Wolters-Kluwer Consultant outside the submitted work. Dr Brophy reported receiving personal fees from UpToDate during the conduct of the study and American Board of Medical Specialities finance board. Dr Charlton reported receiving personal fees from Medtronics Carpediem Clinical Events Committee outside the submitted work. Dr Devarajan reported receiving grants from National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases during the conduct of the study; holding a patent as co-inventor on patents licensed to Abbott Diagnostics and BioPorto Inc, on use of neutrophil gelatinase-associated lipocalin as a biomarker of kidney injury. Dr Gist reported receiving financial support for research from Medtronic Speaker Honorarium and financial support for research from Bioporto Diagnostics consulting fees outside the submitted work. Dr Menon reported receiving personal fees from Nuwellis Inc outside the submitted work. Dr J. Morgan reported receiving personal fees from Medtronic Consultant outside the submitted work. Dr Mottes reported receiving financial support for research from Medtronic outside the submitted work. Dr Stanski reported receiving grants from National Center for Advancing Translational Sciences of the National Institutes of Health Institutional CT2 grant, 2UL1TR001425-05A1 and travel reimbursement from pADQI Travel funds to travel to consensus meeting (flight and hotel) during the conduct of the study; in addition, Dr Stanski reported holding a patent for PERSEVERE-II AKI Prediction Model pending. Dr Zappitelli reported receiving financial support for research from Bioporto Inc adjudicator/consultant for a study on neutrophil gelatinase-associated lipocalin and financial support for research from Baxter Inc Honorarium for a national talk on CRRT (not viewed by company ahead of time) outside the submitted work. Dr Kellum reported receiving personal fees from Dialco; being an employee of Spectral Medical and its wholly owned subsidiary Dialco outside the submitted work; and paid consultant for Astute Medical. Dr Ostermann reported receiving grants from Fresenius Research funding, grants from Baxter Research funding, and grants from Biomerieux Research funding during the conduct of the study. Dr Basu reported receiving personal fees from Bioporto Diagnostics outside of the submitted work. and personal fees from BioMerieux outside of the submitted work. during the conduct of the study; in addition, Dr Basu reported having a patent for Renal Angina Index pending outside of the submitted work. and a patent for olfactomedin-4 pending outside of the submitted work. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Acute Kidney Injury (AKI) Risk Assessment and Dynamic Phenotyping
A, AKI risk assessment should occur in children with a potential kidney insult or any clinical changes to stratify patients into those at standard or high risk for AKI such that kidney-focused care can be implemented. B, Combined with individual susceptibility, multiple elements contribute to discernible AKI phenotypes in affected children that may have prognostic and therapeutic implications. Adapted from the 26th Acute Disease Quality Initiative with permission. These are open access images distributed under the terms of the Creative Commons Attribution License.
Figure 2.
Figure 2.. Development as a Biologic Variable Related to Acute Kidney Injury
The left slope highlights important developmental stages critical to reach optimal kidney function. The right slope represents the normal age-related decrease of kidney function. Acute kidney injury (AKI) can occur at any phase along the developmental trajectory resulting in early kidney compromise and potentially accelerated nephron loss. The timing and degree of AKI likely affect the trajectory to recovery of normal kidney function or persistently decreased function. Research efforts must focus on uncovering and capitalizing on the ways to improve the outlook of an injured kidney. These efforts may include optimization of nutrition, limiting further injury, and novel therapeutics. There are factors that accelerate nephron loss and the trajectory toward kidney failure. The social determinants of health, the types or clusters of AKI, sex as a biologic variable, nutritional factors, and medication dosing are all components that affect the recovery or decrease of kidney function after AKI. Adapted from the 26th Acute Disease Quality Initiative with permission. These are open access images distributed under the terms of the Creative Commons Attribution License.
Figure 3.
Figure 3.. The Role of Education and Advocacy in Pediatric Acute Kidney Injury (AKI)
Education to improve AKI awareness and recognition in children rests on the pillar of advocacy and must engage key stakeholders in developing multidisciplinary context-appropriate customized approaches to improve AKI care globally and across all resource settings. Effective AKI education programs center the child and family, and expand across health care teams, systems, and communities with champions embedded at every level, health care systems, science, and government. AKI education must be a core competency for health care clinicians to ensure that AKI risk mitigation measures are in place to reduce AKI in community and hospital settings, to facilitate early recognition of AKI through technological innovation, and to appropriately manage AKI using context-specific guidelines that recognize the need for continuity of care and clinical follow-up. Implementation of an effective AKI education and advocacy program assures equitable access to diagnostics, emphasizes integrated multidisciplinary collaborative care, and recognizes the unique long-term health outcomes of AKI in children across the life span. Adapted from the 26th Acute Disease Quality Initiative with permission. These are open access images distributed under the terms of the Creative Commons Attribution License.

Comment in

References

    1. Kaddourah A, Basu RK, Bagshaw SM, Goldstein SL; AWARE Investigators. Epidemiology of acute kidney injury in critically ill children and young adults. N Engl J Med. 2017;376(1):11–20. doi:10.1056/NEJMoa1611391 - DOI - PMC - PubMed
    1. Jetton JG, Boohaker LJ, Sethi SK, et al.; Neonatal Kidney Collaborative (NKC). Incidence and outcomes of neonatal acute kidney injury (AWAKEN): a multicentre, multinational, observational cohort study. Lancet Child Adolesc Health. 2017;1(3):184–194. doi:10.1016/S2352-4642(17)30069-X - DOI - PMC - PubMed
    1. Robinson CH, Jeyakumar N, Luo B, et al. Long-term kidney outcomes following dialysis-treated childhood acute kidney injury: a population-based cohort study. J Am Soc Nephrol. 2021;32(8):2005–2019. doi:10.1681/ASN.2020111665 - DOI - PMC - PubMed
    1. Greenberg JH, Zappitelli M, Devarajan P, et al.; TRIBE-AKI Consortium. Kidney outcomes 5 years after pediatric cardiac surgery: The TRIBE-AKI Study. JAMA Pediatr. 2016;170(11):1071–1078. doi:10.1001/jamapediatrics.2016.1532 - DOI - PMC - PubMed
    1. Madsen NL, Goldstein SL, Frøslev T, Christiansen CF, Olsen M. Cardiac surgery in patients with congenital heart disease is associated with acute kidney injury and the risk of chronic kidney disease. Kidney Int. 2017;92(3):751–756. doi:10.1016/j.kint.2017.02.021 - DOI - PubMed

Publication types